Zogenix is expanding its pipeline beyond lead drug Fintepla, saying Monday it will pay $250 million upfront to acquire Modis Therapeutics, a privately-held biotech developing a treatment for an ultra-rare neuromuscular disorder.
In April, the U.S. Food and Drug Administration (FDA) issued a Refuse to File (RTF) letter to Zogenix for its New Drug Application (NDA) for Fintepla (fenfluramine hydrochloride). The drug was developed to treat seizures associated with Dravet syndrome, a rare form of epilepsy characterized by frequent and prolonged seizures.